These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. The impact of Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508 [TBL] [Abstract][Full Text] [Related]
4. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285 [TBL] [Abstract][Full Text] [Related]
5. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981 [TBL] [Abstract][Full Text] [Related]
6. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study. Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A; Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of Kassem TW; Abdelaziz O; Emad-Eldin S Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778 [TBL] [Abstract][Full Text] [Related]
9. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195 [TBL] [Abstract][Full Text] [Related]
10. Role of Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849 [TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma. Liu Y Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435 [TBL] [Abstract][Full Text] [Related]
13. The use of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography as an effective method for staging in dogs with primary appendicular osteosarcoma. Crooks C; Randall E; Griffin L Vet Radiol Ultrasound; 2021 May; 62(3):350-359. PubMed ID: 33629412 [TBL] [Abstract][Full Text] [Related]
14. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073 [TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
16. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Basu D; Siegel BA; McDonald DJ; Nussenbaum B Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620 [TBL] [Abstract][Full Text] [Related]
17. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700 [TBL] [Abstract][Full Text] [Related]
18. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314 [TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826 [TBL] [Abstract][Full Text] [Related]
20. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]